TY - JOUR T1 - Response: The most fundamental change in asthma management in 30 years? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01860-2019 VL - 54 IS - 5 SP - 1901860 AU - Helen K. Reddel A2 - , Y1 - 2019/11/01 UR - http://erj.ersjournals.com/content/54/5/1901860.abstract N2 - I. Amirav and M.T. Newhouse have commented on the April 2019 recommendations by the Global Initiative for Asthma (GINA) that, for safety, adults and adolescents with asthma should not be treated with short-acting bronchodilators alone, and that instead, to reduce the risk of serious exacerbations, they should receive either symptom-driven (in mild asthma) or daily ICS-containing treatment (www.ginasthma.org/reports). The background evidence and rationale for the GINA recommendations were further explained in an editorial published in the European Respiratory Journal [1].GINA recommends against treating asthma in adults and adolescents with SABAs alone. Large studies support as-needed low dose ICS–formoterol, which is available in several formulations, as a feasible solution to reduce risk in mild asthma. http://bit.ly/2l5X0H4 ER -